Abstract
Tzanck smear test is a low-cost, rapid and reliable tool which can be used for the diagnosis of many erosive-vesiculobullous, tumoral and granulomatous diseases. Currently its use is limited mainly due to lack of experience in interpretation of the smears. We developed a deep learning model, TzanckNet, that can identify cells in Tzanck smear test findings. TzanckNet was trained on a retrospective development dataset of 2260 Tzanck smear images collected between December 2006 and December 2019. The finalized model was evaluated using a prospective validation dataset of 359 Tzanck smear images collected from 15 patients during January 2020. It is designed to recognize six cell types (acantholytic cells, eosinophils, hypha, multinucleated giant cells, normal keratinocytes and tadpole cells). For 359 images and 6 cell types, TzanckNet made 2154 predictions. The accuracy was 94.3% (95% CI 93.4–95.3), the sensitivity was 83.7% (95% CI 80.3–87.0) and the specificity was 97.3% (95% CI 96.5–98.1). The area under the receiver operating characteristic curve was 0.974. Our results show that TzanckNet has the potential to lower the experience barrier needed to use this test, broadening its user base, and hence improving patient well-being.
Highlights
Tzanck smear test is a low-cost, rapid and reliable tool which can be used for the diagnosis of many erosive-vesiculobullous, tumoral and granulomatous diseases
The reality is quite the opposite. This method can be used for the diagnosis of many erosive-vesiculobullous, tumoral and granulomatous diseases, its use is usually limited to herpes virus infections in daily dermatology p ractice[2]
We fixed a discrimination threshold of 0.5 such that if the predicted probability for any cell type was above this threshold, the model predicted that this cell type existed in the image
Summary
Tzanck smear test is a low-cost, rapid and reliable tool which can be used for the diagnosis of many erosive-vesiculobullous, tumoral and granulomatous diseases. A dermatopathological diagnostic tool first described in 1 9471, costs less than a dollar, gives results in less than an hour, causes minimal patient discomfort, does not require anesthesia and is a ccurate[2]. This method can be used for the diagnosis of many erosive-vesiculobullous, tumoral and granulomatous diseases, its use is usually limited to herpes virus infections in daily dermatology p ractice[2]. In some clinics, this test is not used even for the diagnosis of herpes virus infections; instead patients receive local anesthesia followed by a skin biopsy[3].
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have